Zentalis Pharmaceuticals IPO

4/2/2020

IPO

$176,400,000

approximately $60.0 million to advance the clinical development of ZN-c5, including to complete our ongoing Phase 1/2 clinical trial of ZN-c5 as a monotherapy and in combination with palbociclib in patients with ER+/HER2- advanced or metastatic breast cancer; approximately $25.0 million to advance the clinical development of ZN-c3, including to complete our ongoing Phase 1/2 clinical trial in patients with advanced solid tumors; approximately $15.0 million to advance the development of ZN-d5 into clinical trials, including to complete our planned Phase 1 clinical trial in patients with AML or B-cell lymphoma; approximately $5.0 million to advance the clinical development of ZN-e4, including to complete the Phase 1 portion of our ongoing Phase 1/2 clinical trial in patients with advanced NSCLC with activating EGFR mutations; and the remainder for the design and development of new product candidates leveraging our Integrated Discovery Engine and for working capital and other general corp

Publicly-held

Biopharmaceutical

530 Seventh Ave. 2201
New York, NY 10018
USA

At Zentalis (Nasdaq: ZNTL), we are developing clinically differentiated therapeutics targeting fundamental cancer pathways that have the potential to address major unmet medical needs for patients with cancer. We have successfully advanced three compounds into the clinic in the Company's first five years, all internally developed using the deep chemistry capabilities of our integrated discovery engine.